Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
28M
-
Number of holders
-
32
-
Total 13F shares, excl. options
-
1.91M
-
Shares change
-
-98.8K
-
Total reported value, excl. options
-
$11.9M
-
Value change
-
-$744K
-
Put/Call ratio
-
0.39
-
Number of buys
-
12
-
Number of sells
-
-13
-
Price
-
$6.20
Significant Holders of Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB) as of Q3 2022
41 filings reported holding INMB - Inmune Bio, Inc. - Common Stock, par value $0.001 per share as of Q3 2022.
Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB) has 32 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.91M shares
of 28M outstanding shares and own 6.84% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (541K shares), BlackRock Inc. (233K shares), Janney Montgomery Scott LLC (195K shares), ACT CAPITAL MANAGEMENT, LLC (151K shares), GEODE CAPITAL MANAGEMENT, LLC (140K shares), MORGAN STANLEY (129K shares), DEUTSCHE BANK AG\ (121K shares), ROYAL BANK OF CANADA (60.5K shares), STATE STREET CORP (45K shares), and UBS Group AG (40K shares).
This table shows the top 32 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.